Linyi Liu

Title: Linyi Liu - Innovator in Antitumor Compounds

Introduction

Linyi Liu is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of antitumor research through his innovative work on compounds targeting the BCR-ABL protein. His research focuses on developing effective treatments for tumors associated with this protein.

Latest Patents

Linyi Liu holds a patent for "Compounds targeting and degrading BCR-ABL protein and its antitumor application." This patent describes a compound that shows degradation and inhibitory effects on the BCR-ABL target protein. The compound is comprised of four moieties, including a compound moiety with BCR-ABL tyrosine kinase inhibited activity, link units, a small molecule ligand for VHL or CRBN proteases, and a carbonyl group that covalently binds to the other moieties. The designed compounds demonstrate extensive pharmacological effectiveness, functioning to degrade BCR-ABL protein and inhibit its activity, making them potential candidates for treating relevant tumors.

Career Highlights

Linyi Liu is affiliated with ShanghaiTech University, where he conducts his research and development work. His innovative approach to targeting the BCR-ABL protein has positioned him as a key figure in the field of cancer research.

Collaborations

Linyi Liu collaborates with notable colleagues, including Xiaobao Yang and Biao Jiang. Their combined expertise enhances the research efforts in developing effective antitumor therapies.

Conclusion

Linyi Liu's contributions to the field of antitumor research through his innovative compounds targeting the BCR-ABL protein highlight his role as a significant inventor. His work has the potential to lead to new treatments for tumors, showcasing the importance of innovation in medical research.